ライフサイエンスコーパス: liraglutide

1 (oral semaglutide superiority vs placebo and liraglutide).

2 rive the largest benefit from treatment with liraglutide.

3 and improved metabolic parameters similar to liraglutide.

4 Glp1r(-/-) mice or C57BL/6 mice treated with liraglutide.

5 increased in mice treated with exendin-4 or liraglutide.

6 DegLira, 414 to insulin degludec, and 415 to liraglutide.

7 gludec, and by 1.3% (1.1) to 7.0% (1.2) with liraglutide.

8 ral semaglutide were similar to subcutaneous liraglutide.

9 rointestinal adverse events were higher with liraglutide.

10 al and in line with previous experience with liraglutide.

11 once weekly titrated to 50 mg at week 6, or liraglutide 0.6 mg once daily titrated to 1.2 mg at week

12 eceived subcutaneous injections of saline or liraglutide (0.005-0.015 mg/kg/day) for 30 days after am

13 ere treated for 8 days with the GLP-1 analog liraglutide (0.2 mg/kg twice daily), which restored NO b

14 ed for 8 weeks with either vehicle (PO, QD), liraglutide (0.4 mg/kg, SC, QD), elafibranor (30 mg/kg,

15 CI -0.58 to -0.36, p<0.0001) and superior to liraglutide (-0.64%, -0.75 to -0.53, p<0.0001).

16 aim was to assess the safety and efficacy of liraglutide 1.8 mg in patients with persistent or recurr

17 er-generated sequence to either subcutaneous liraglutide 1.8 mg once daily or placebo, both given tog

18 igh cardiovascular risk were assigned 1:1 to liraglutide (1.8 mg daily or maximum tolerated dose up t

19 centres to assess subcutaneous injections of liraglutide (1.8 mg daily) compared with placebo for pat

20 subcutaneous liraglutide (3.0 mg) (n = 423), liraglutide (1.8 mg) (n = 211), or placebo (n = 212), al

21 s were reported with liraglutide (3.0 mg) vs liraglutide (1.8 mg) and placebo.

22 .3% with liraglutide (3.0 mg) and 40.4% with liraglutide (1.8 mg) vs 21.4% with placebo (estimated di

23 .2% with liraglutide (3.0 mg) and 15.9% with liraglutide (1.8 mg) vs 6.7% with placebo (estimated dif

24 ce-weekly dulaglutide (1.5 mg) or once-daily liraglutide (1.8 mg).

25 ith liraglutide (3.0-mg dose), 105.8 kg with liraglutide (1.8-mg dose), and 106.5 kg with placebo.

26 iraglutide (3.0-mg dose), 4.7% (5.0 kg) with liraglutide (1.8-mg dose), and 2.0% (2.2 kg) with placeb

27 with oral semaglutide than with subcutaneous liraglutide (-1.5 kg, 95% CI -2.2 to -0.9; p<0.0001) and

28 placebo, -4.00% [95% CI, -5.10% to -2.90%]; liraglutide [1.8 mg] vs placebo, -2.71% [95% CI, -4.00%

29 placebo, 32.9% [95% CI, 24.6% to 41.2%]; for liraglutide [1.8 mg] vs placebo, 19.0% [95% CI, 9.1% to

30 8.5% [95% CI, 12.7% to 24.4%], P < .001; for liraglutide [1.8 mg] vs placebo, 9.3% [95% CI, 2.7% to 1

31 Liraglutide 3.0 mg might provide health benefits in term

32 web-based system, to once-daily subcutaneous liraglutide 3.0 mg or matched placebo, as an adjunct to

33 Liraglutide 3.0 mg was shown to reduce bodyweight and im

34 tients were given degludec 100 units/mL plus liraglutide 3.6 mg/mL in a 3 mL prefilled PDS290 pen for

35 Once-daily, subcutaneous liraglutide (3.0 mg) (n = 423), liraglutide (1.8 mg) (n

36 loss greater than 10% occurred in 25.2% with liraglutide (3.0 mg) and 15.9% with liraglutide (1.8 mg)

37 loss of 5% or greater occurred in 54.3% with liraglutide (3.0 mg) and 40.4% with liraglutide (1.8 mg)

38 ts with type 2 diabetes, use of subcutaneous liraglutide (3.0 mg) daily, compared with placebo, resul

39 re randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once dail

40 th no stratification to receive subcutaneous liraglutide (3.0 mg) or placebo, with standardised nutri

41 In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a sig

42 astrointestinal disorders were reported with liraglutide (3.0 mg) vs liraglutide (1.8 mg) and placebo

43 Baseline weight was 105.7 kg with liraglutide (3.0-mg dose), 105.8 kg with liraglutide (1.

44 Weight loss was 6.0% (6.4 kg) with liraglutide (3.0-mg dose), 4.7% (5.0 kg) with liraglutid

45 weight loss (-4.4 kg [SE 0.2]) compared with liraglutide (-3.1 kg [SE 0.2]; ETD -1.2 kg, 95% CI -1.9

46 2 kg) with placebo (estimated difference for liraglutide [3.0 mg] vs placebo, -4.00% [95% CI, -5.10%

47 6.7% with placebo (estimated difference for liraglutide [3.0 mg] vs placebo, 18.5% [95% CI, 12.7% to

48 21.4% with placebo (estimated difference for liraglutide [3.0 mg] vs placebo, 32.9% [95% CI, 24.6% to

49 kly dulaglutide (299 patients) or once-daily liraglutide (300 patients).

50 amate, 8.8 kg (95% CrI, -10.20 to -7.42 kg); liraglutide, 5.3 kg (95% CrI, -6.06 to -4.52 kg); naltre

51 omization, 134 received at least one dose of liraglutide (66 patients) or placebo (68 patients).

52 In a 52-week study with liraglutide, a dose-related increase in absolute pancrea

53 Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor

54 The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when ad

55 a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with pl

56 antidiabetic activities of NRTN relative to liraglutide, a glucagon-like peptide 1 receptor agonist,

57 Liraglutide, a glucagon-like peptide-1 analogue, has bee

58 Liraglutide, a glucagon-like peptide-1 analogue, improve

59 Liraglutide, a long-acting GLP-1 receptor agonist, is ap

60 example, we showed that the prescription of liraglutide, a type 2 diabetes drug, is significantly as

61 the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanzapine treatment o

62 Whether liraglutide added to metformin (with or without basal in

63 stinal adverse events reported with degludec/liraglutide (adverse events, 79 for degludec/liraglutide

64 Adverse events with liraglutide affected mainly the gastrointestinal tract.

65 e investigate the neuroprotective effects of Liraglutide along with the signalling network against pr

66 The administration of sCT with liraglutide also led to a significant enhancement in cFo

67 Oral semaglutide, empagliflozin, and liraglutide also reduced cardiovascular death.

68 Besides lowering blood glucose, liraglutide also reduces body weight.

69 support the relative renal safety profile of liraglutide among patients with HFrEF.

70 LP-1 analogues showed efficacy comparable to liraglutide, an antidiabetic GLP-1 analogue that carries

71 24 (45%) of 53 patients assigned to liraglutide and 11 (41%) of 27 assigned to placebo repor

72 tudy population consisted of 23 402 users of liraglutide and 23 402 matched users of DPP-4 inhibitors

73 6 patients were randomly assigned to receive liraglutide and 26 to placebo.

74 s similar in the two groups (56 [84.8%] with liraglutide and 55 [80.9%] with placebo), but the overal

75 had decreased by 0.64 percentage points with liraglutide and increased by 0.42 percentage points with

76 s significant interest in combination use of liraglutide and phentermine for weight loss; however, bo

77 trate that in obese mice, the combination of liraglutide and phentermine may reduce body weight but o

78 The combination of liraglutide and phentermine, at 100 mug/kg/day and 10 mg

79 in decreasing bodyweight compared with both liraglutide and placebo at week 26.

80 The liraglutide and placebo groups had comparable characteri

81 LP-1 agonist, was compared with subcutaneous liraglutide and placebo in patients with type 2 diabetes

82 he glucagon-like peptide-1 receptor agonists liraglutide and semaglutide also reduced CV death and/or

83 semaglutide was non-inferior to subcutaneous liraglutide and superior to placebo in decreasing HbA(1c

84 tem based on hydrogen bond formation between liraglutide and TA and stabilized by complex coordinatio

85 Nine (39%) of 23 patients who received liraglutide and underwent end-of-treatment liver biopsy

86 The relationship between randomization to liraglutide and WRF was evaluated using logistic regress

87 argin: 0.4%] and superiority vs subcutaneous liraglutide) and the confirmatory secondary endpoint was

88 emaglutide, -1.1% (SE 0.1) with subcutaneous liraglutide, and -0.2% (SE 0.1) with placebo.

89 r patient year was 1.8 for IDegLira, 0.2 for liraglutide, and 2.6 for insulin degludec.

90 the antihyperglycaemic drugs empagliflozin, liraglutide, and semaglutide-the latter being under revi

91 besity; however, the mechanisms of action of liraglutide are incompletely understood.

92 d (FA) moiety that causes oligomerization of liraglutide as suggested by small-angle x-ray scattering

93 In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was ass

94 In this large Scandinavian cohort, use of liraglutide, as compared with use of DPP-4 inhibitors, w

95 nd defective responses to the GLP-1 analogue liraglutide at 8 weeks.

96 eceive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or place

97 weight control than daily injection of free liraglutide at the same treatment dose.

98 ildren and adolescents with type 2 diabetes, liraglutide, at a dose of up to 1.8 mg per day (added to

99 Liraglutide blocked glycolysis in T cells and decreased

100 Moreover, labeled liraglutide bound neurons within the arcuate nucleus (AR

101 mediate body weight and anorectic effects of liraglutide, but are not required for glucose-lowering e

102 Further, P-NT and liraglutide coadministration improved glycemia and reduc

103 Overall, our data suggest that P-NT and liraglutide combination therapy could be an enhanced tre

104 for the full synergistic effect of P-NT and liraglutide combination therapy.

105 MS-275 and liraglutide combined therapy improved fasting glycemia u

106 Body weight decreased with liraglutide compared with placebo (-5.3 kg; 95% CI, -7.0

107 ; 95% CI, -23.2 to -7.7 mg/dL) occurred with liraglutide compared with placebo.

108 rgine and metformin, treatment with degludec/liraglutide compared with up-titration of glargine resul

109 cardiovascular events associated with use of liraglutide, compared with an active comparator drug cla

110 exone-bupropion, phentermine-topiramate, and liraglutide, compared with placebo, were each associated

111 ere also administered the anti-diabetic drug liraglutide daily beginning at day 39 of the CGM monitor

112 Although liraglutide decreased glucose levels, it did not restore

113 Compared with placebo, liraglutide delayed gastric emptying of solids at 5 week

114 Hearts from animals treated with liraglutide demonstrated decreased beta1-adrenoreceptor

115 LP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was

116 h heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization

117 Here, we determined that liraglutide does not activate GLP-1-producing neurons in

118 escalated to 14 mg), once-daily subcutaneous liraglutide (dose escalated to 1.8 mg), or placebo for 5

119 wed an increase in the exocrine cell mass in liraglutide-dosed animals, with normal composition of en

120 (Liraglutide Effect and Action in Diabetes: Evaluation of

121 using GLP-1R agonists addressing this issue (Liraglutide Effect and Action in Diabetes: Evaluation of

122 rdiovascular events and mortality in LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of

123 e GLP-1R agonists liraglutide (LEADER trial [Liraglutide Effect and Action in Diabetes: Evaluation of

124 Mechanistically, Liraglutide engages Akt and signal transducer and activa

125 Liraglutide enhanced the slope of the relationship betwe

126 decreases in HbA(1c) than both subcutaneous liraglutide (ETD -0.2%, 95% CI -0.3 to -0.1; p=0.0056) a

127 fat-fed mice treated with the GLP-1R agonist liraglutide exhibited preservation of cardiac function.

128 21 trials), oral semaglutide, empagliflozin, liraglutide, extended-release exenatide, and dapaglifloz

129 icle formulation offers sustained release of liraglutide for >8 days by optimizing the concentration

130 ertensive effect of repeated LV injection of liraglutide for 14 days was also attenuated.

131 ly dulaglutide is non-inferior to once-daily liraglutide for least-squares mean reduction in HbA1c, w

132 ermined SAXS curves supporting the view that liraglutide forms heptamers in solution.

133 sea was the most common adverse event in the liraglutide group (12 of 19) compared with placebo (four

134 ients died from cardiovascular causes in the liraglutide group (219 patients [4.7%]) than in the plac

135 ate of death from any cause was lower in the liraglutide group (381 patients [8.2%]) than in the plac

136 urred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in

137 lerated volume at 16 weeks, was lower in the liraglutide group (median 750 mL [IQR 651 to 908]) compa

138 tal of 125 participants were assigned to the liraglutide group and 126 to the placebo group.

139 disorders in 21 (81%) of 23 patients in the liraglutide group and 17 (65%) of 22 patients in the pla

140 withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the plac

141 seline HbA1c level was 8.4% for the degludec/liraglutide group and 8.2% for the glargine group.

142 as observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the p

143 ents occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the pla

144 of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and

145 A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo

146 vel had decreased at both time points in the liraglutide group but had increased in the placebo group

147 Glucose tolerance improved in the liraglutide group compared with the placebo group (P < .

148 required eight (38%) of 21 successes in the liraglutide group for the effect of liraglutide to be co

149 At week 56, patients in the liraglutide group had lost a mean of 8.4+/-7.3 kg of bod

150 rticipants in the IDegLira group than in the liraglutide group reported gastrointestinal adverse even

151 which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215

152 utcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668

153 lso significantly greater weight loss in the liraglutide group than in the placebo group (at 5 weeks:

154 More participants in the liraglutide group than in the placebo group had gastroin

155 ncreatitis was nonsignificantly lower in the liraglutide group than in the placebo group.

156 t failure were nonsignificantly lower in the liraglutide group than in the placebo group.

157 week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo g

158 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 indivi

159 f 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in

160 Two (9%) of 23 patients in the liraglutide group versus eight (36%) of 22 patients in t

161 glutide vs glargine (-1.81% for the degludec/liraglutide group vs -1.13% for the glargine group; esti

162 primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P = .31)

163 ces in the number of deaths (19 [12%] in the liraglutide group vs 16 [11%] in the placebo group; haza

164 ted hyperglycemic events was 16 (10%) in the liraglutide group vs 27 (18%) in the placebo group and h

165 ncluded diarrhoea (ten [38%] patients in the liraglutide group vs five [19%] in the placebo group), c

166 61 [20%] in dulaglutide group vs 54 [18%] in liraglutide group), diarrhoea (36 [12%] vs 36 [12%]), dy

167 the oral semaglutide group, 274 (96%) in the liraglutide group, and 134 (94%) in the placebo group co

168 One suicide, which occurred in the liraglutide group, was assessed by the investigator as u

169 e dulaglutide group and -1.36% (0.05) in the liraglutide group.

170 in degludec group, and 14 (3%) of 412 in the liraglutide group.

171 e enrolled and randomly allocated (19 to the liraglutide group; 21 to the placebo group).

172 Compared with placebo, liraglutide had no significant effect on the primary end

173 Compared to GLP-1, liraglutide has an added fatty acid (FA) moiety that cau

174 the glucagon-like peptide-1 (GLP-1) analogue liraglutide has been developed as a once-daily injection

175 h subgroups, fewer deaths were observed with liraglutide (HR: 0.89 [95% CI: 0.70 to 1.14] with HF; HR

176 ated the durability of insulin degludec plus liraglutide (IDegLira) versus insulin glargine 100 units

177 lucagon-like peptide (GLP)-1 analogs such as liraglutide improved albuminuria in patients with type 2

178 either the synthetic GLP-1 receptor agonist liraglutide in a dose-escalating regimen to reverse hype

179 on, and, recently, a pilot clinical trial of Liraglutide in Alzheimer's disease patients showed impro

180 semaglutide was non-inferior to subcutaneous liraglutide in decreasing HbA(1c) (estimated treatment d

181 e-weekly dulaglutide with that of once-daily liraglutide in metformin-treated patients with uncontrol

182 eripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in

183 dy weight caused by the central injection of liraglutide in other hypothalamic sites was sufficiently

184 o assess the cardiovascular effectiveness of liraglutide in routine clinical practice.

185 port for the cardiovascular effectiveness of liraglutide in routine clinical practice.

186 These findings do not support the use of liraglutide in this clinical situation.

187 jection of a clinically used GLP-1R agonist, liraglutide, in mice stimulates brown adipose tissue (BA

188 efficacy of the long-acting GLP-1 analogue, liraglutide, in patients with non-alcoholic steatohepati

189 ists, once-weekly albiglutide and once-daily liraglutide, in patients with type 2 diabetes inadequate

190 nion are orlistat, naltrexone/bupropion, and liraglutide; in the USA, lorcaserin and phentermine/topi

191 rdiovascular event occurred in 1132 users of liraglutide (incidence rate 14.0 per 1000 person-years)

192 Liraglutide increased diastolic relaxation (dP/dt; Tau (

193 Liraglutide induced greater weight loss than placebo at

194 his area is sufficient to blunt both central liraglutide-induced thermogenesis and adipocyte browning

195 /CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.

196 Acute administration of liraglutide into fourth ventricle, the area with easy ac

197 Liraglutide is a GLP-1 receptor agonist recently approve

198 Liraglutide is a glucagon-like peptide-1 (GLP-1) analog

199 Liraglutide is an acylated glucagon-like peptide-1 (GLP-

200 The glucagon-like peptide 1 (GLP-1) analog, liraglutide, is a GLP-1 agonist and is used in the treat

201 rdiovascular event) with the GLP-1R agonists liraglutide (LEADER trial [Liraglutide Effect and Action

202 diabetic retinopathy (DR) were neutral with liraglutide (LEADER) or worse when compared with placebo

203 of native GLP-1 and several GLP-1R agonists (liraglutide, lixisenatide, and exenatide).

204 Liraglutide may be useful for weight management in adole

205 We show that Liraglutide modulates the ER stress response and elicits

206 ity with improved tolerability compared with liraglutide monotherapy.

207 The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily s

208 1:1 randomization to degludec/liraglutide (n = 278; maximum dose, 50 U of degludec/1.8

209 e randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749).

210 l semaglutide (n=229 [80%]) and subcutaneous liraglutide (n=211 [74%]) than with placebo (n=95 [67%])

211 ed to oral semaglutide (n=285), subcutaneous liraglutide (n=284), or placebo (n=142).

212 8, we assigned 80 patients to receive either liraglutide (n=53) or placebo (n=27).

213 istory of NYHA functional class I to III HF (liraglutide: n = 835 of 4,668; placebo: n = 832 of 4,672

214 Liraglutide, naltrexone/bupropion, and phentermine/topir

215 Interestingly, coadministration of NRTN and liraglutide normalized hyperglycemia and other metabolic

216 this study was to investigate the effects of liraglutide on cardiovascular events and mortality in LE

217 However, the long-term effects of liraglutide on renal outcomes in patients with type 2 di

218 Effects of liraglutide on the composite of HF hospitalization or ca

219 INTERPRETATION: Effects of liraglutide on weight loss are associated with delay in

220 entricular (LV) injection of GLP-1R agonist, liraglutide, once daily for 15 days counteracted the dev

221 The cohort included incident users of liraglutide or DPP-4 inhibitors, who were also using met

222 Liraglutide or placebo was escalated by 0.6 mg/day each

223 ks with once-daily subcutaneous injection of liraglutide or placebo.

224 l in which patients were assigned to receive liraglutide or placebo.

225 ia spectrum disorder, 103 were randomized to liraglutide or placebo.

226 etes and high cardiovascular risk to receive liraglutide or placebo.

227 ting of all participants who received either liraglutide or placebo.

228 eral adipose tissue in patients who received liraglutide or sitagliptin and then reported these add-o

229 gon-like peptide 1 receptor (GLP-1R) agonist liraglutide or the highly selective DPP4 inhibitor MK-06

230 e T cells were stimulated in the presence of liraglutide or vehicle.

231 Compared with placebo, liraglutide (OR, 2.95; 95% CrI, 2.11-4.23) and naltrexon

232 85; SUCRA, 0.95), 63% of participants taking liraglutide (OR, 5.54; 95% CrI, 4.16-7.78; SUCRA, 0.83),

233 78; maximum dose, 50 U of degludec/1.8 mg of liraglutide) or glargine (n = 279; no maximum dose), wit

234 ntractility) increased with dobutamine after liraglutide (P < 0.001) but not saline administration (P

235 imepiride, insulin glargine, insulin lispro, liraglutide, pioglitazone, or sitagliptin).

236 mmol/L) in the presence of GLP-1 (100 nmol/L liraglutide) presented a greater SIRT6 and lower nuclear

237 systemic administration of a GLP-1R agonist (liraglutide) prevents retinal neurodegeneration (glial a

238 nd GLP-1 analogs salmon calcitonin (sCT) and liraglutide produce synergistic-like reductions in 24 ho

239 e in cystatin C among patients randomized to liraglutide raising concern of adverse renal outcomes.

240 risk of HF hospitalization was observed with liraglutide, regardless of HF history (HR: 0.98 [95% CI:

241 alysis shows that, when added to usual care, liraglutide resulted in lower rates of the development a

242 who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end p

243 d ZDF rats with sustained hyperglycemia with liraglutide resulted in some alleviation of hyperglycemi

244 d with change in weight loss at week 16 with liraglutide (Rs 0.567, p=0.018).

245 of changes in total liver mass revealed that liraglutide's efficacy reached statistical significances

246 ll cardiovascular efficacy for lixisenatide, liraglutide, semaglutide, and extended-release exenatide

247 Based on these findings, liraglutide should be considered suitable for patients w

248 vitro, T cells stimulated in the presence of liraglutide showed decreased proliferation of TH1 and TH

249 Liraglutide significantly improved glucose tolerance, bo

250 r weight was accounted for, both INT-767 and liraglutide significantly reduced biopsy-based total col

251 While INT-767 and liraglutide significantly reduced total liver weight by

252 the glucagon-like peptide-1 receptor agonist liraglutide significantly reduces the risk of major card

253 holic fatty liver disease (NAFLD) to receive liraglutide, sitagliptin, or insulin glargine as add-on

254 re identified: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN 6 (semaglutide), and EXSCEL (exten

255 were included: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide

256 In this study, we developed a ternary liraglutide/tannic acid (TA)/Al(3+) nanoparticle system

257 al-3 levels (P < 0.001), whereas INT-767 and liraglutide tended to reduce relative col1a1 levels.

258 omised individuals was 2.7 times longer with liraglutide than with placebo (95% CI 1.9 to 3.9, p<0.00

259 I standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.1

260 A greater reduction was observed with liraglutide than with placebo for BMI (estimated differe

261 with type 2 diabetes mellitus was lower with liraglutide than with placebo.

262 ned with the glucagon-like peptide 1 mimetic liraglutide, the two peptides synergized to reduce food

263 s in the liraglutide group for the effect of liraglutide to be considered clinically significant.

264 are also required for peripherally injected liraglutide to reduce feeding and weight.

265 Altogether, 30 liraglutide-treated participants (63.8%) developed norma

266 However, unlike liraglutide-treated rats, NRTN-mediated improvements wer

267 These findings support the use of adjunctive liraglutide treatment in patients with persistent or rec

268 s were elevated in STZ-DM rats, and although liraglutide treatment lowered glucagon levels to those o

269 Liraglutide treatment provided beneficial glucose-loweri

270 Chronic liraglutide treatment reduced body weight in chow-fed GL

271 Liraglutide treatment significantly improved the renal o

272 A(1c) levels and surgery type as covariates, liraglutide treatment was associated with a difference o

273 ss and proliferation rates were unaltered by liraglutide treatment.

274 ned, in a 1:1 ratio, to receive subcutaneous liraglutide (up to 1.8 mg per day) or placebo for a 26-w

275 We compared effects of liraglutide versus placebo on gastric motor functions, s

276 Effects of liraglutide versus placebo on major adverse cardiovascul

277 recent hospitalization for heart failure to liraglutide versus placebo.

278 ght gain with glargine (-1.4 kg for degludec/liraglutide vs 1.8 kg for glargine; ETD, -3.20 kg [95% C

279 liraglutide (adverse events, 79 for degludec/liraglutide vs 18 for glargine).

280 des/patient-year exposure, 2.23 for degludec/liraglutide vs 5.05 for glargine; estimated rate ratio,

281 1c level reduction was greater with degludec/liraglutide vs glargine (-1.81% for the degludec/liraglu

282 If noninferiority of degludec/liraglutide was achieved, secondary end points were test

283 Treatment with degludec/liraglutide was also associated with weight loss compare

284 Furthermore, use of liraglutide was associated with a significantly lower ri

285 ompared with use of DPP-4 inhibitors, use of liraglutide was associated with a significantly lower ri

286 hoc analysis of FIGHT to investigate whether liraglutide was associated with worsening renal function

287 gon-like peptide-1 receptor (GLP-1R) agonist liraglutide was designed, synthesized, and tested.

288 LP1R in the CNS or visceral nerves; however, liraglutide was ineffective at altering food intake, bod

289 In the ARC, liraglutide was internalized in neurons expressing proop

290 In adjusted models, liraglutide was not associated with excess risk of WRF c

291 Liraglutide was not associated with WRF among patients w

292 Liraglutide was safe, well tolerated, and led to histolo

293 Liraglutide was superior to placebo with regard to the c

294 Phentermine-topiramate and liraglutide were associated with the highest odds of ach

295 rse events leading to the discontinuation of liraglutide were gastrointestinal events.

296 most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea.

297 of peripherally dosed GLP-1RA exendin-4 and liraglutide were preserved in all mouse lines.

298 .06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased.

299 portant to know the oligomerization state of liraglutide with respect to stability.

300 The primary hypothesis was that liraglutide would be noninferior to placebo with regard